Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
McKinsey
McKesson
Baxter
Medtronic

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

ARANESP Drug Profile

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for ARANESP

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Leiden University Medical CenterPhase 2/Phase 3
The Hospital for Sick ChildrenPhase 2
Sanquin-LUMC J.J van Rood Center for Clinical Transfusion ResearchPhase 2/Phase 3

See all ARANESP clinical trials

Recent Litigation for ARANESP

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Ameranth, Inc. v. Starbucks Corporation2013-05-06

See all ARANESP litigation

Pharmacology for ARANESP
Ingredient-typeErythropoietin
Physiological EffectIncreased Erythroid Cell Production

Company Disclosures: US Patents for ARANESP

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 001 2001-09-17   Start Trial Kirin-Amgen, Inc. (Thousand Oaks, CA) 2003-12-13 RX company
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 001 2001-09-17   Start Trial Amgen Inc. (Thousand Oaks, CA) 2024-05-15 RX company
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 002 2001-09-17   Start Trial Kirin-Amgen, Inc. (Thousand Oaks, CA) 2003-12-13 RX company
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 002 2001-09-17   Start Trial Amgen Inc. (Thousand Oaks, CA) 2024-05-15 RX company
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 003 2001-09-17   Start Trial Kirin-Amgen, Inc. (Thousand Oaks, CA) 2003-12-13 RX company
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 003 2001-09-17   Start Trial Amgen Inc. (Thousand Oaks, CA) 2024-05-15 RX company
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 004 2001-09-17   Start Trial Kirin-Amgen, Inc. (Thousand Oaks, CA) 2003-12-13 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for ARANESP

These patents were identified by searching patent claims

Supplementary Protection Certificates for ARANESP

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
PA2004015 Lithuania   Start Trial PRODUCT NAME: DARBEPOETINAS ALFA (ASN30 THR32 VAL87 ASN88 THR90 EPO); REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608
43/2001 Austria   Start Trial PRODUCT NAME: DARBEPOETIN-ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608
SPC/GB01/055 United Kingdom   Start Trial PRODUCT NAME: DARBEPOETIN ALFA; REGISTERED: UK EU/1/01/185/001-030 20010608
01C0050 France   Start Trial PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608
10199059 Germany   Start Trial PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608
300075 Netherlands   Start Trial PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608
SZ 43/2001 Austria   Start Trial PRODUCT NAME: DARBEPOETIN-ALFA
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Medtronic
Boehringer Ingelheim
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.